insights_auto
Pse është rritur MVIR 2,33%?
Zhytu më thellëchevron_right
MVIR:STO
Medivir AB
1,49Â SEK
arrow_upward
+2,33%(+0,034) 1D
9 tet, 5:29:42 m.d., GMT+2 · SEK
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për MVIR...
Hap
1,47Â SEK
I lartë
1,50Â SEK
I ulët
1,45Â SEK
Kapitalizimi i tregut
932,52Â mln
Vëllimi mesatar
1,41Â mln
Vëllimi
1,73Â mln
Maksimumi 52-javor
2,88Â SEK
Minimumi 52-javor
0,34Â SEK
Fitimet për aksion
-0,37Â SEK
Aksionet në qarkullim
624,18Â mln
Numri i punonjësve
6
Hap
1,47Â SEK
I lartë
1,50Â SEK
I ulët
1,45Â SEK
Kapitalizimi i tregut
932,52Â mln
Vëllimi mesatar
1,41Â mln
Vëllimi
1,73Â mln
Maksimumi 52-javor
2,88Â SEK
Minimumi 52-javor
0,34Â SEK
Fitimet për aksion
-0,37Â SEK
Aksionet në qarkullim
624,18Â mln
Numri i punonjësve
6
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Simply Wall Street
·
12 minuta më parë
Will Higher Royalty Revenue Change Vicor (VICR) Stock Narrative
Simply Wall Street
·
1 orë më parë
Why Peloton Interactive Fell Even As Profit Rose
Nasdaq
·
14 orë më parë
WISeSat.Space Holdings Corp. Rings the Opening Bell
Profili
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Rreth Medivir AB